As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

MS/MS Standards

MS/MS Products

MS/MS Screening Mixtures and Standards


  • MS/MS Screening Mixtures and Standards
  • The Use of Stable Isotope-Enriched Standards as a Key Component of the MS/MS Analysis of Metabolites Extracted from Dried Blood Spots
Details and applications of our offerings (both sets and individuals) for MS/MS screening and tuning are noted in the resources and referencs below. In particular, the MS/MS Screening Standards catalog lists the composition details and reconstitution recommendations (for concentrated and working stocks), but also the usage specifications (i.e., storage and recommended retest date before and after reconstitution) for our reference standard sets. The sets contain a collection of stable isotope-labeled standards (e.g., 12 amino acids in NSK-A) and are available in a 10-vial set or as single vials. CIL also has the ability to customize standards or mixes to meet your specific needs. Please inquire for details.
 
 

Frequently Asked Questions 

What is the recommended procedure for solubilizing NSK-A and -B?

The lyophilized amino acid mix in NSK-A (and NSK-A1) should  be dissolved in 1 mL of 50:50 purified water:methanol and the carnitine/acylcarnitines in NSK-B (and NSK-B-G1) in 1 mL of  purified methanol. Following the solvent addition, each vial should be vortexed manually for 1 min then auto-vortexed for 30 min (or longer until fully solubilized).

Are the component chemical purities considered in the NSK product formulations?

Yes, the chemical purity of each component (as stated on the CoA) is reviewed at time of formulation and the gravimetry is adjusted as necessary to compensate for chemical purity.

What concentration should I use on the CoA to represent the standard in use – gravimetric target concentration, concentration by gravimetry, or analyzed concentration?

The concentrations presented in the “Concentration by Gravimetry” column of the CoA should be used to represent the actual concentration of each component after reconstitution.


References

Young, A.; Hendricks, J.; Foreman, D.; et al. 2020. Development of dried blood spot quality control materials for adenosine deaminase severe combined immunodeficiency and an LC-MS/MS method for their characterization. Clin Mass Spec, 17, 4-11. DOI: 10.1016/j.clinms.2020.07.002
 
Yang, Y.; Wu, Z.; Li, S.; et al. 2020. Targeted blood metabolomic study on retinopathy of prematurity. Invest Ophthalmol Vis Sci, 61(2), 12. PMID: 32049343
 
Sun, R.; Li ,Y.; Cai, M.; et al. 2019. Discovery of a new biomarker pattern for differential diagnosis of acute ischemic stroke using targeted metabolomics. Front Neurol, 10, 1011. PMID: 31608005
 
Matthew, E.M.; Lewis, L.; Rao, P.; et al. 2019. Novel HILIC-ESI-MS method for urinary profiling of MSUD and methylmalonic aciduria biomarkers. J Chromatogr Sci, 57(8), 715-723. PMID: 31251316
 
Jack, R.M.; Scott, C.R. 2019. Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion. JIMD Rep, 46(1), 75-78.  PMID: 31240158
 
Bai, Q.; Peng, B.; Wu, X.; et al. 2018. Metabolomic study for essential hypertension patients based on dried blood spot mass spectrometry approach. IUBMB Life, 70(8), 777-785. PMID: 30092118
 
Jacob, M.; Malkawi, A.; Albast, N.; et al. 2018. A targeted metabolomics approach for clinical diagnosis of inborn errors of metabolism. Anal Chim Acta, 1025, 141-153. PMID: 29801603
 
Coene, K.L.M.; Kluijtmans, L.A.J.; van der Heeft, E.; et al. 2018. Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients. J Inherit Metab Dis, 41(3), 337-353. PMID: 29453510
 
Ribas, G.; De Mari, J.F.; Civallero, G.; et al. 2017. Validation of a multiplex tandem mass spectrometry method for the detection of selected lysosomal storage diseases in dried blood spots. JIMES, 5, 1-7. doi.org/10.1177%2F2326409817692360.
 
Céspedes, N., Valencia, A., Echeverry, C.A., et al. 2017. Reference values of amino acids, acylcarnitines and succinylacetone by tandem mass spectrometry for use in newborn screening in southwest Colombia. Colomb Med, 48(3), 113-119. PMID: 29213153
 
de Sain-van der Velden, M.G.M.; van der Ham, M.; Gerrits, J.; et al. 2017. Quantification of metabolites in dried blood spots by direct infusion high resolution mass spectrometry. Anal Chim Acta, 979, 45-50. PMID: 28599708
 
Tortorelli, S.; Turgeon, C.T.; Gavrilov, D.K.; et al. 2016. Simultaneous testing for 6 lysosomal storage disorders and x-adrenoleukodystrophy in dried blood spots by tandem ass spectrometry. Clin Chem, 62(9), 1248-1254. PMID: 27440509
 
Huang, T.; Cao, Y.; Zeng, J.; et al. 2016. Tandem mass spectrometry-based newborn screening strategy could be used to facilitate rapid and sensitive lung cancer diagnosis. Onco Targets Ther9, 2479-2487. PMID: 27217771
 
Prinsen, H.C.M.T.; Schiebergen-Bronkhorst, B.G.M.; Roeleveld, M.W.; et al. 2016. Rapid quantification of underivatized amino acids in plasma by hydrophilic interaction liquid chromatography (HILIC) coupled with tandem mass spectrometry. J Inherit Metab Dis, 39(5), 651-660. PMID: 27099181
 
Cho, S.E.; Kwak, J.R.; Lee, H.; et al. 2016. Triplex tandem mass spectrometry assays for the screening of 3 lysosomal storage disorders in a Korean population. Clin Chim Acta, 454, 20-27. PMID: 26707915
 
George, R.S.; Moat, S.J. 2016. Effect of dried blood spot quality on newborn screening analyte concentrations and recommendations for minimum acceptance criteria for sample analysis. Clin Chem, 62(3), 466-475. PMID: 26647314
 
Haynes, C.A.; De Jesús, V.R. 2016. Simultaneous quantitation of hexacosanoyl lysophosphatidylcholine, amino acids, acylcarnitines, and succinylacetone during FIA-ESI-MS/MS analysis of dried blood spot extracts for newborn screening. Clin Biochem49(1-2), 161-165. PMID: 26432925
 
Miller, M.J.; Kennedy, A.D.; Eckhart, A.D.; et al. 2015. Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism. J Inherit Metab Dis, 38(6), 1029-1039. PMID: 25875217
 
Held, P.K.; Haynes, C.A.; De Jesús, V.R.; et al. 2014. Development of an assay to simultaneously measure orotic acid, amino acids, and acylcarnitines in dried blood spots. Clin Chem Acta, 436, 149-154. PMID: 24886687
 
Chace, D.H.; Kalas, T.A.; Naylor, E.W. 2003. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem, 49, 1797-1817. PMID: 14578311
Krista Backiel

Krista Backiel

Marketing Manager and Metabolomics Manager

Krista Backiel is responsible for managing and promoting products that are utilized in metabolomics and clinical/diagnostic MS. She spends a lot of her time developing new products to assist customers in their diverse research efforts.

More
Andrew Percy, PhD

Andrew Percy, PhD

Senior Applications Chemist – Mass Spectrometry

Dr. Andrew Percy is the Senior Applications Chemist for Mass Spectrometry. His responsibilities minimally involve overseeing product development, identifying new product market opportunities, assisting in the analysis of products for MS ‘omics applications, and providing technical support to customers.

More

Related Products

Carnitine/Acylcarnitine Standards

Amino Acid Standards

Substrates & Internal Standards

Organic Acid Standards

Other Standards


*CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.

To view information on our CE mark* products click here. Their instructions for use can be obtained here.